Alkem Laboratories appoints Amrut Naik as chief executive officer from 11 Nov 2026
- Management change
- Pharmaceuticals
Reviewed byRachit TripathiBlacklitt Research
Alkem Laboratories (NSE: ALKEM) has appointed Dr. Amrut Naik as Chief Executive Officer and Key Managerial Personnel with effect from 11 Nov 2026, it said in a filing on 03 Nov 2026. The board made the appointment at its meeting on 03 Nov 2026, on the recommendation of the Nomination and Remuneration Committee.
Terms and background of the appointment
The board appointed Dr. Amrut Naik on the recommendation of the Nomination and Remuneration Committee. The appointment runs for as long as he remains in the employment of the company, according to the filing.
The company describes Naik as a seasoned global pharmaceutical business leader with 26-plus years of hands-on experience in building, scaling and transforming global businesses across branded formulations, generics, APIs, biologics, vaccines, specialty and innovation-led portfolios. He holds a Ph.D. (Tech) in Pharmacology, a Master's in Pharmaceutical Science and a Bachelor's in Pharmaceutical Science.
The company states that there are no disclosed relationships between directors.
What the appointment means for Alkem Laboratories' shareholders
The filing records a change in the company's top executive role, effective 11 Nov 2026, with the appointee's background set out in the company's own words. The filing does not state the reason for the appointment, whether the role is held by an internal director or an external hire, who the outgoing chief executive is, or his remuneration. The company's plans under the new chief executive are not stated.
At a glance
| Item | Detail |
|---|---|
| Appointee | Dr. Amrut Naik |
| Role | Chief Executive Officer and Key Managerial Personnel |
| Board approval | 03 Nov 2026 |
| Effective date | 11 Nov 2026 |
| Term | As long as he is in the employment of the company |
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
